Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 9/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8332561 | 1.00 | PYGL (0.61) | PYGLHIF1AKDM4EGMNNLMNA | |
| SCHEMBL6538568 | 0.83 | PYGL (0.63) | PYGLHIF1AKDM4EGMNNLMNA | |
| SCHEMBL6538415 | 0.83 | PYGL (0.63) | PYGLHIF1AKDM4EGMNNLMNA | |
| SCHEMBL27498579 | 0.80 | PYGL (0.56) | PYGLHIF1AKDM4EGMNNLMNA | |
| SCHEMBL5310180 | 0.80 | ADORA1 (0.46) | PYGL | |
| SCHEMBL3810104 | 0.80 | PYGL (0.39) | PYGL | |
| SCHEMBL187957 | 0.79 | FBP1 (0.50) | SMN1; SMN2 | |
| SCHEMBL8619293 | 0.77 | PYGL (0.63) | PYGLHIF1AKDM4EGMNNLMNA | |
| SCHEMBL9239176 | 0.77 | PYGL (0.63) | PYGLHIF1AKDM4EGMNNLMNA | |
| SCHEMBL8152014 | 0.74 | PYGL (0.55) | PYGLHIF1AKDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618084-B2 | Method for producing transformant | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2026-05-05 | — | — | US | disclosed |
| US-12338454-B2 | Helper plasmid for transformation, method for producing transformant using the same, and transformation method | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2025-06-24 | — | — | US | disclosed |
| US-20240043855-A1 | A HELPER PLASMID FOR TRANSFORMATION, A METHOD FOR PRODUCING A TRANSFORMANT USING THE SAME, AND A METHOD OF TRANSFORMATION | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2024-02-08 | — | — | US | disclosed |
| US-20240043875-A1 | A PLASMID FOR TRANSFORMATION, A METHOD FOR PRODUCING A TRANSFORMANT USING THE SAME AND A METHOD OF TRANSFORMATION | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2024-02-08 | — | — | US | disclosed |
| US-20240002885-A1 | PLASMID FOR TRANSFORMATION, METHOD FOR PRODUCING TRANSFORMANT USING THE SAME, AND TRANSFORMATION METHOD | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-110494131-B | Application of spermine and derivatives thereof in preparation of antitumor drugs | 广州君赫生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022138647-A1 | A HELPER PLASMID FOR TRANSFORMATION, A METHOD FOR PRODUCING A TRANSFORMANT USING THE SAME, AND A METHOD OF TRANSFORMATION | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022138649-A1 | A PLASMID FOR TRANSFORMATION, A METHOD FOR PRODUCING A TRANSFORMANT USING THE SAME, AND A METHOD OF TRANSFORMATION | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022118866-A1 | PLASMID FOR TRANSFORMATION, METHOD FOR PRODUCING TRANSFORMANT USING THE SAME, AND TRANSFORMATION METHOD | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2022-06-09 | — | — | WO | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20140248689-A1 | GLUCOSE-INDUCED INACTIVATION/DEGRADATION-RESISTANT TRANSPORTER GENE AND USE THEREOF | SUNTORY HOLDINGS LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-8735092-B2 | Glucose-induced inactivation/degradation-resistant transporter gene and use thereof | SUNTORY HOLDINGS LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2202300-B1 | GLUCOSE-INDUCED INACTIVATION/DEGRADATION RESISTANT TRANSPORTER GENE AND USE THEREOF | SUNTORY HOLDINGS LTD (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-20110104331-A1 | GLUCOSE-INDUCED INACTIVATION/DEGRADATION-RESISTANT TRANSPORTER GENE AND USE THEREOF | SUNTORY HOLDINGS LIMITED (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2202300-A1 | GLUCOSE-INDUCED INACTIVATION/DEGRADATION RESISTANT TRANSPORTER GENE AND USE THEREOF | Suntory Holdings Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618084-B2 | Method for producing transformant | SRRT, RAD52, FEN1 | PYGL 1668/4885HIF1A 3409/4885KDM4E 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.